GLP‐1 agonists vs placebo
Adverse events ‐ weight loss · adults with Parkinson's disease
GLP‐1 receptor agonists showed no clear difference in adverse events ‐ weight loss compared with placebo (low certainty).
1 finding from 1 review
- RR 1.25 [0.89, 1.76]1 study · 60 participantsLow